Gritstone bio (GRTS) Revenue & Revenue Breakdown
Gritstone bio Revenue Highlights
Latest Revenue (Y)
$16.34M
Latest Revenue (Q)
$49.00K
Main Segment (Y)
Grant
Gritstone bio Revenue by Period
Gritstone bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $16.34M | 76.33% |
| 2022-12-31 | $9.27M | -80.16% |
| 2021-12-31 | $46.72M | 1057.22% |
| 2020-12-31 | $4.04M | -7.51% |
| 2019-12-31 | $4.37M | 267.73% |
| 2018-12-31 | $1.19M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Gritstone bio generated $16.34M in revenue during NA 2023, up 76.33% compared to the previous quarter, and up 1376.92% compared to the same period a year ago.
Gritstone bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $49.00K | 68.97% |
| 2023-12-31 | $29.00K | -98.15% |
| 2023-09-30 | $1.56M | 291.25% |
| 2023-06-30 | $400.00K | -26.20% |
| 2023-03-31 | $542.00K | -59.16% |
| 2022-12-31 | $1.33M | 204.36% |
| 2022-09-30 | $436.00K | -84.21% |
| 2022-06-30 | $2.76M | -41.81% |
| 2022-03-31 | $4.75M | 166.57% |
| 2021-12-31 | $1.78M | -25.86% |
| 2021-09-30 | $2.40M | -15.55% |
| 2021-06-30 | $2.84M | -92.84% |
| 2021-03-31 | $39.69M | 2842.40% |
| 2020-12-31 | $1.35M | 43.66% |
| 2020-09-30 | $939.00K | 92.42% |
| 2020-06-30 | $488.00K | -61.33% |
| 2020-03-31 | $1.26M | 42.76% |
| 2019-12-31 | $884.00K | -10.16% |
| 2019-09-30 | $984.00K | -14.43% |
| 2019-06-30 | $1.15M | -14.63% |
| 2019-03-31 | $1.35M | 23.46% |
| 2018-12-31 | $1.09M | 1036.46% |
| 2018-09-30 | $96.00K | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Gritstone bio generated $49.00K in revenue during Q1 2024, up 68.97% compared to the previous quarter, and up 3.69% compared to the same period a year ago.
Gritstone bio Revenue Breakdown
Gritstone bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Collaboration Revenue | $300.00K | - | - | - |
| License | $1.33M | $9.27M | $46.72M | $3.46M |
| Grant | $15.01M | $10.68M | $1.50M | - |
| Contribution | - | - | - | $575.00K |
Gritstone bio's latest annual revenue breakdown by segment (product or service), as of Dec 23: Grant (90.20%), License (8.00%), and Collaboration Revenue (1.80%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License | $57.00K | $49.00K | $389.00K | $400.00K | $542.00K | $1.33M | $436.00K | $2.76M | $4.75M | $1.78M | $2.40M | $918.00K | $795.00K |
| Grant | $864.00K | $1.69M | $11.56M | $1.55M | $1.90M | $2.94M | $2.58M | $2.71M | $2.45M | $1.28M | $213.00K | - | - |
| Contribution | - | - | - | - | - | - | - | - | - | - | - | $431.00K | $144.00K |
Gritstone bio's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Grant (93.81%), and License (6.19%).
Gritstone bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SGMO | Sangamo Therapeutics | $176.23M | $356.00K |
| AUPH | Aurinia Pharmaceuticals | $158.53M | $55.03M |
| HRTX | Heron Therapeutics | $127.04M | $46.54M |
| GTHX | G1 Therapeutics | $82.51M | $16.55M |
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| GRTS | Gritstone bio | $16.34M | $49.00K |
| BBIO | BridgeBio Pharma | $9.30M | $2.17M |
| AFMD | Affimed | $8.28M | $155.00K |
| KZR | Kezar Life Sciences | $7.00M | - |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| FULC | Fulcrum Therapeutics | $2.81M | $80.00M |
| ALLO | Allogene Therapeutics | $95.00K | $22.00K |
| IFRX | InflaRx | $61.80K | $36.25K |
| CRVS | Corvus Pharmaceuticals | - | - |
| APTO | Aptose Biosciences | - | - |
| CCCC | C4 Therapeutics | - | - |
| LPTX | Leap Therapeutics | - | - |
| ERAS | Erasca | - | - |
| ANNX | Annexon | - | - |
| PASG | Passage Bio | - | - |
| ANVS | Annovis Bio | - | - |
| EWTX | Edgewise Therapeutics | - | - |
GRTS Revenue FAQ
What is Gritstone bio’s yearly revenue?
Gritstone bio's yearly revenue for 2023 was $16.34M, representing an increase of 76.33% compared to 2022. The company's yearly revenue for 2022 was $9.27M, representing a decrease of -80.16% compared to 2021. GRTS's yearly revenue for 2021 was $46.72M, representing an increase of 1057.22% compared to 2020.
What is Gritstone bio’s quarterly revenue?
Gritstone bio's quarterly revenue for Q1 2024 was $49K, a 68.97% increase from the previous quarter (Q4 2023), and a -90.96% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $29K, a -98.15% decrease from the previous quarter (Q3 2023), and a -97.81% decrease year-over-year (Q4 2022). GRTS's quarterly revenue for Q3 2023 was $1.56M, a 291.25% increase from the previous quarter (Q2 2023), and a 258.94% increase year-over-year (Q3 2022).
What is Gritstone bio’s revenue growth rate?
Gritstone bio's revenue growth rate for the last 3 years (2021-2023) was -65.01%, and for the last 5 years (2019-2023) was 274.43%.
What are Gritstone bio’s revenue streams?
Gritstone bio's revenue streams in c 23 are Collaboration Revenue, License, and Grant. Collaboration Revenue generated $300K in revenue, accounting 1.80% of the company's total revenue License generated $1.33M in revenue, accounting 8.00% of the company's total revenue, down -85.64% year-over-year. Grant generated $15.01M in revenue, accounting 90.20% of the company's total revenue, up 40.62% year-over-year.
What is Gritstone bio’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Gritstone bio was Grant. This segment made a revenue of $15.01M, representing 90.20% of the company's total revenue.